NM_001034853.2(RPGR):c.389T>G (p.Phe130Cys) is a missense variant predicted to cause substitution of phenylalanine by cysteine at amino acid 130. This variant is absent from hemizygous individuals in gnomAD v4.1.0 (PM2_Supporting). The computational predictor REVEL gives the variant a score of 0.764, which is between the ClinGen X-linked IRD VCEP threshold of 0.644 to 0.773 and predicts a damaging effect on RPGR function (PP3). The computational splicing predictor SpliceAI gives a delta score of 0.05 for donor loss, which is below the ClinGen X-linked IRD VCEP threshold of >0.2 and does not predict that the variant disrupts RPGR splicing. The variant protein has shown severely decreased interaction with RPGRIP1 in a yeast-2-hybrid assay (PMID: 10958648, PMID: 23213406), as well as complete mislocalization to the cytoplasm rather than to the primary cilium (PMID: 30622176) and disrupted interactions with PDE6D, RPGRIP1L, and INPP5E (PMID: 30622176, PS3_supporting). At least one proband harboring this variant exhibits a phenotype including early onset (1), family history consistent with X-linked inheritance (2) with a milder phenotype in females (1), pigmentary retinopathy (0.5), optic nerve pallor (0.5), and decreased central visual acuity (0.5), which together are specific for RPGR-related retinopathy (5.5 points, PP4, personal communication with clinician regarding an unpublished proband). The variant has been reported to segregate with retinal dystrophy through at least 1 affected meiosis (an affected mother and her son) from 1 family. (PP1, personal communication with author). In summary, this variant is classified as a variant of uncertain significance for RPGR-related retinopathy based on the ClinGen X-linked Inherited Retinal Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for RPGR Version 1.0.0; PS3_Supporting, PM2_Supporting, PP3, PP4, and PP1. (date of approval 05/16/2025).